RecruitingPhase 2NCT06962098

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects With Diabetic Kidney Disease

Sponsor

Aptabio Therapeutics, Inc.

Enrollment

186 participants

Start Date

May 26, 2025

Study Type

INTERVENTIONAL

Conditions

Diabetic Kidney Disease (DKD)

Summary

This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Isuzinaxib and a drug called Placebo for people with diabetic kidney disease (dkd). The study is currently recruiting participants at 20 locations. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIsuzinaxib

Oral dosing regimen once daily

DRUGPlacebo

Oral dosing regimen once daily

Locations(20)

Korea University Ansan Hospital

Ansan-si, South Korea

Inje university Busan Paik Hospital

Busan, South Korea

Pusan National University Hospital

Busan, South Korea

SoonChunHyang University Hospital Cheonan

Cheonan, South Korea

Keimyung University Daegu Dongsan Hospital

Daegu, South Korea

Inje university Ilsan Paik Hospital

Goyang-si, South Korea

Hanyang University Guri Hospital

Guri-si, South Korea

Chung-Ang University Gwangmyeong Hospital

Gwangmyeong, South Korea

The Catholic University of Korea Incheon St. Mary's Hospital

Incheon, South Korea

Jeonbuk National University Hospital

Jeonju, South Korea

CHA Bundang Medical Center

Seongnam-si, South Korea

Boramae Medical Center

Seoul, South Korea

Korea University Guro Hospital

Seoul, South Korea

Kyung Hee University Hospital at Gangdon

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital

Seoul, South Korea

The Catholic University of Korea Seoul ST.MARY'S Hospital

Seoul, South Korea

The Catholic University of Korea Uijeongbu St. Mary's Hospital

Uijeongbu-si, South Korea

Wonju Severance Christian Hospital

Wŏnju, South Korea

Pusan National University Yangsan Hospital

Yangsan, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06962098

Related Trials

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

NCT0727118651 locations

Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

NCT069698076 locations